The scale is not the whole story
Phase 2 studies · 2023–2025 publications
The weight fell. What else changed?
Subject One steps off the scale and rehearses a triumphant bow. A second bell rings: HEART RATE. A third: BODY COMPOSITION. “How many judges are there?” Doctide points toward the safety desk. Subject One abandons the bow and asks for a chair.
What changes here
The weight-loss result was striking, but heart rate, gastrointestinal effects and lean-mass changes also mattered. [1] [4]
Read the study details & dates
The obesity trial
A 48-week Phase 2 trial enrolled 338 adults. The highest studied arm averaged 24.2% weight reduction versus 2.1% with placebo. Gastrointestinal events were common; dose-related heart-rate increases peaked around week 24 and later declined. [1]
A separate diabetes trial
A parallel Phase 2 trial enrolled 281 participants with type 2 diabetes, assessing glucose control and weight against placebo and dulaglutide. This was a different population, not the next visit for the obesity cohort. [2]
Looking beyond total weight
A substudy measured lower liver fat by MRI; that does not prove prevention of liver failure or reversal of fibrosis. A separate body-composition analysis found some lean-mass loss alongside fat reduction, so “all weight lost is fat” is not accurate. [3] [4]
What this does not establish
A large average weight change is not the whole safety or benefit record. The character does not inherit the average outcome, and these measurements do not establish every longer-term clinical benefit.
Original sources
- Jastreboff et al., Phase 2 obesity trial
- Rosenstock et al., Phase 2 diabetes trial
- Liver-fat substudy (2024)
- Body-composition substudy (2025)
Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story